A highly sensitive and specific assay for detection of Trichomonas vaginalis. Utilizes proven APTIMA assay technology and TIGRIS and PANTHER system automation. Tests the same samples used for APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae. Utilizes proven APTIMA assay technology and TIGRIS system automation. Tests the same samples used for APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae.

A COMMON PROBLEM
Trichomonas vaginalis is a sexually transmitted parasite that can cause vaginitis, urethritis, premature membrane rupture in pregnancy, and makes women more susceptible to infection with HIV-1. The World Health Organization estimates that there are 180 million new cases of Trichomonas infection annually worldwide, making it even more prevalent than Chlamydia and gonorrhea, the most common bacterial sexually transmitted infections. Screening for Trichomonas is limited today in part due to the shortfalls of current testing techniques. Most testing currently is done via culture methods, which are slower and less sensitive than molecular tests, or "wet mount," which requires the microscopic examination of a sample shortly after it is collected.

A BETTER TESTING OPTION
The APTIMA Trichomonas vaginalis Assay is a nucleic acid amplification test (NAAT) for the detection of T. vaginalis. The assay utilizes the same technology as the APTIMA COMBO 2 Assay and may use the same specimens as those used with APTIMA COMBO 2 Assay (clinician-collected vaginal and endocervical swabs, female urine and PreservCyt solution). The APTIMA Trichomonas vaginalis Assay is currently available for use on the TIGRIS and PANTHER instruments.

The APTIMA Trichomonas vaginalis assay was cleared for In Vitro Diagnostic Use by the FDA in 2011. APTIMA Trichomonas vaginalis assay is CE marked for IVD use.

For additional availability in other countries please contact your local sales rep or distributor

Performance Data